This review summarizes the roles of noncoding RNAs in liver fibrosis and hepatocellular carcinoma, indicating their potential as biomarkers and therapeutic targets.
Liver diseases constitute a major global health burden, contributing substantially to morbidity and mortality worldwide. Although effective therapeutic strategies have been developed for key risk factors, such as hepatitis C infection, therapeutic options for most other liver diseases remain limited. Noncoding RNAs (ncRNAs), which regulate diverse cellular and molecular processes, have emerged as promising therapeutic targets and biomarkers in liver diseases. In this study, we summarize the mechanisms of action and functional roles of ncRNAs, such as long ncRNAs (lncRNAs), circular RNAs (circRNAs), and PIWI–interacting RNAs (piRNAs), to improve therapeutic strategies and diagnostic precision in liver diseases, such as liver fibrosis and hepatocellular carcinoma (HCC).
No takes yet. Share an insight, caveat, or question.
Sohn et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: